SNY does have some interesting antithrombotics in the pipeline (#msg-22938795); however, Otamixaban won’t be on the market until 2012 at the earliest. For the most part, the late-stage FXa drug candidates are pills intended for chronic use.
The main point, of course, is that none of these drugs can be considered a competitor of ATryn. Regards, Dew
Market Data 
Markets 
AI
